GHRP-6 Mechanism of Action

Introduction

GHRP-6 (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2) is a synthetic hexapeptide that acts as a full agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), also referred to as the ghrelin receptor. The receptor target for GHRP-6 was elucidated through a research trajectory spanning from the peptide's initial characterization in 1984 [1] through receptor cloning in 1996 [2] and the discovery of the endogenous ligand ghrelin in 1999 [3]. This article summarizes reported molecular interactions and downstream pharmacological effects as described in published peer-reviewed literature. For a summary of the preclinical and human pharmacokinetic studies conducted with this compound, see the GHRP-6 published research article.

Receptor Target and Binding

GHS-R1a is a class A (rhodopsin-like) G protein-coupled receptor (GPCR) expressed predominantly in the arcuate nucleus of the hypothalamus and the anterior pituitary gland, with additional expression sites documented in multiple peripheral tissues [4]. Howard and colleagues reported the receptor's molecular cloning in 1996, identifying it as a seven-transmembrane domain protein of 364–366 amino acids that is highly conserved across species [2].

A 2022 cryo-electron microscopy study by Zhao and colleagues resolved the structural basis for GHRP-6 and ghrelin binding to GHS-R1a [5]. The authors reported that both ligands occupy the same orthosteric binding pocket — comprising transmembrane helices 2 through 7 and extracellular loops 2 and 3 — but adopt distinct orientational modes. Ghrelin inserts its acylated N-terminus deep into the helical bundle, whereas GHRP-6 binds in an inverted orientation with its C-terminus penetrating the bundle and its histidine N-terminus facing the extracellular vestibule [5]. This structural characterization provides a foundation for understanding the differences in signaling bias observed between the two ligands.

An unusual property of GHS-R1a, noted across multiple independent studies, is its high constitutive (ligand-independent) activity — estimated at approximately 50% of maximal receptor capacity in the absence of any ligand [6]. This constitutive activity carries physiological significance; a loss-of-function mutation impairing GHS-R1a constitutive signaling has been associated with familial short stature, indicating the receptor's basal activity contributes to endogenous GH secretion [6].

Reported Molecular Interactions and Intracellular Signaling

Upon GHRP-6 binding, GHS-R1a couples primarily to the Gαq/11 heterotrimeric G protein subunit. Published mechanistic studies have described the following intracellular cascade in pituitary somatotroph cells [7, 8]:

Gαq/11 activation of phospholipase C-β (PLCβ) cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum; DAG activates protein kinase C (PKC) isoforms. PKC activity subsequently gates voltage-dependent calcium channels in the plasma membrane, resulting in extracellular calcium entry. The combined elevation of intracellular calcium — from both intracellular stores and extracellular influx — serves as the primary second messenger driving GH exocytosis from somatotroph secretory granules.

Kamegai and colleagues (1996) examined calcium dynamics in dispersed rat somatotroph cells and reported that the GHRP-6 response required both intracellular calcium mobilization and extracellular calcium entry, indicating a dual-source calcium signal [8].

Crosstalk with the cyclic adenosine monophosphate (cAMP) pathway has also been described. A study of human pituitary somatotropinomas reported that GHRP-6 dose-dependently stimulated phosphoinositide (PI) hydrolysis and cAMP generation in tumor cell preparations, with this activity linked to protein kinase C-dependent activation of adenylyl cyclase [9]. At the hypothalamic level, GHRP-6 has been reported to modulate growth hormone-releasing hormone (GHRH) and somatostatin release, with published evidence describing synergistic interactions between GHRP-6 and GHRH at the pituitary level — yielding GH responses in animal models exceeding the additive effects of either peptide alone [1].

CD36 Receptor Interactions

In addition to GHS-R1a, GHRP-6 has been reported to interact with CD36, a class B scavenger receptor expressed on cell types including macrophages, monocytes, adipocytes, and various epithelial and endothelial cells. Berlanga-Acosta and colleagues characterized CD36 as a pharmacologically relevant binding target for GHRP-6, proposing that this interaction underlies cytoprotective and antifibrotic effects observed in animal models that are mechanistically distinct from the GHS-R1a–mediated GH-releasing pathway [10].

CD36 engagement has been associated in the published literature with modulation of the peroxisome proliferator-activated receptor gamma (PPARγ) pathway and downstream effects on inflammatory cytokine expression. A wound healing study in rodent models reported that topical GHRP-6 application was associated with attenuation of pro-inflammatory mediators and reduction of fibrogenic cytokine expression in granulation tissue, with the authors attributing these observations partly to CD36-mediated signaling [11].

Downstream Effects in Published Animal Research

Published preclinical research has described a range of downstream observations following GHRP-6 administration in animal models. These findings derive from in vitro cell culture and in vivo animal experiments.

In cardiac tissue, Granado and colleagues (2006) examined a porcine model of acute myocardial infarction and reported reductions in myocardial infarct mass and necrotic area in GHRP-6-treated animals compared to saline controls, with decreased reactive oxygen species and preservation of antioxidant enzyme activity described [12]. The authors proposed findings consistent with an anti-apoptotic signaling profile involving modulation of the Bcl-2/Bax ratio.

In hepatic tissue, published studies in rodent models of experimentally induced liver fibrosis have reported histomorphological differences in collagen deposition between GHRP-6-treated and control animals [10]. The mechanistic basis proposed in those publications included modulation of TGF-β1 signaling and stellate cell activation — research areas that remain under active investigation at the preclinical stage.

Areas of Ongoing Investigation

Several mechanistic questions raised by the published literature represent active research frontiers. The structural basis for GHRP-6's inverted binding orientation relative to ghrelin — and the pharmacological consequences of this orientational difference for downstream signaling bias — was only recently characterized at the structural level in 2022 [5], providing a foundation for functional validation studies. Related GHS-R1a agonists such as ipamorelin represent the same pharmacological class and have been studied with overlapping signaling characterization methods. The relative contributions of GHS-R1a versus CD36 to GHRP-6's observed pharmacological profile across different tissue and cell types represent an open research question that systematic comparative studies are positioned to address. Published mechanistic data derive predominantly from rodent and porcine animal models, and translation to human biology is an area of ongoing investigation.

References

1. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537–45. PMID: 6714155. https://pubmed.ncbi.nlm.nih.gov/6714155/

2. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–7. PMID: 8688086.

3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60. PMID: 10604470. https://pubmed.ncbi.nlm.nih.gov/10604470/

4. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87(6):2988. PMID: 12050285. https://pubmed.ncbi.nlm.nih.gov/12050285/

5. Zhao LH, Yin Y, Yang D, Liu B, Gu L, Ren Y, et al. Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor. Nat Commun. 2022;13(1):4476. PMC: PMC8379176. https://pmc.ncbi.nlm.nih.gov/articles/PMC8379176/

6. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest. 2006;116(3):760–8. PMC: PMC1386123. https://pubmed.ncbi.nlm.nih.gov/16511602/

7. Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621–45. PMID: 9331547.

8. Kamegai J, Hasegawa O, Minami S, Sugihara H, Wakabayashi I. The growth hormone-releasing peptide receptor gene is expressed in the neonatal and adult rat brain. Neuroendocrinology. 1996;64(1):1–5. PMID: 8869737.

9. Cella SG, Peroni M, Tagliaferri V, Lucini V, Locatelli V, Müller EE. Protein kinase C-dependent growth hormone releasing peptides stimulate cAMP production by human pituitary somatotropinomas. J Clin Endocrinol Metab. 1996;81(8):2777–82. PMID: 8721987. https://pubmed.ncbi.nlm.nih.gov/8721987/

10. Berlanga-Acosta J, Guillén-Nieto G, Rodríguez-Rodríguez N, Bringas-Vega ML. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Mediators Inflamm. 2017;2017:9274040. PMC: PMC5392015. https://pmc.ncbi.nlm.nih.gov/articles/PMC5392015/

11. García-Ojalvo A, Pavon-Fuentes N, Llópiz-Arzuaga A, Fernández-Mayola M, Pedraza-Rivero L, Castel-Ruiz R, et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Adv Skin Wound Care. 2016;29(7):315–20. PMC: PMC4854984. https://pmc.ncbi.nlm.nih.gov/articles/PMC4854984/

12. Granado M, Martín AI, Priego T, Villanúa MA, López-Calderón A. Growth hormone-releasing peptide 6 (GHRP6) prevents myocardial injury and necrosis in a model of acute myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;292(1):H547–53. PMID: 16989643. https://pubmed.ncbi.nlm.nih.gov/16989643/